Volumetric MRI and MRS provide sensitive measures of Alzheimer's disease neuropathology in inducible Tau transgenic mice (rTg4510)

The purpose of this study was to determine if in vivo high resolution 3D MRI and localized (1)H MR spectroscopy (MRS) can detect brain findings resembling Alzheimer's disease in a transgenic mouse model of Tau pathology. Seven double transgenic rTg4510 female mice and 7 age-matched wild-type (wt) female mice were evaluated at 5 months of age. To confirm the usefulness and consistency of in vivo MRI/S, we also scanned the brains of 14 male mice (7 rTg4510 and 7 age-matched wt) at 8 months of age. Mean hippocampal and cerebral cortex volumes in the female rTg4510 mice were 26.7% and 20.6% smaller than that in the wt controls (p<0.0001), respectively. Mean hippocampal and cerebral cortex volumes in the male rTg4510 mice were 18.4% and 16.9% smaller than that in the wt controls (p<0.00005), respectively. The mean volumes of the cerebellum were not statistically different between the rTg4510 and the wt groups. MRS assessment revealed that the myo-inositol to total creatine ratios (mIns/tCr), a measure of gliosis, were significantly higher in the hippocampus of rTg4510 mice relative to wt mice (p=0.03 for the females; p=0.005 for the males). Immunohistochemistry and histology in the same animals verified previously published data showing elevation of hyperphosphorylated Tau, glial activation and cortical and hippocampal neuronal loss. This study demonstrates that in vivo MRI/S can be a non-invasive biomarker to assess brain atrophy and related biochemical changes in the rTg4510 mouse model.

[1]  Helene Benveniste,et al.  Tracking Brain Volume Changes in C57BL/6J and ApoE-Deficient Mice in a Model of Neurodegeneration: A 5-Week Longitudinal Micro-MRI Study , 2001, NeuroImage.

[2]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[3]  C. Jack,et al.  Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia , 2002, Neurology.

[4]  S. Provencher.  Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[5]  James C. Gee,et al.  Two algorithms for non-rigid image registration and their evaluation , 2003, SPIE Medical Imaging.

[6]  E G Tangalos,et al.  1H MR spectroscopy in common dementias , 2004, Neurology.

[7]  M. Goedert,et al.  Molecular Pathogenesis of Genetic and Inherited Diseases Induction of Inflammatory Mediators and Microglial Activation in Mice Transgenic for Mutant Human P301S Tau Protein , 2004 .

[8]  P. Thompson,et al.  PET of brain amyloid and tau in mild cognitive impairment. , 2006, The New England journal of medicine.

[9]  C. Janus,et al.  Sex difference in pathology and memory decline in rTg4510 mouse model of tauopathy , 2011, Neurobiology of Aging.

[10]  L. Thal,et al.  Astroglial Activation of Extracellular-Regulated Kinase in Early Stages of Alzheimer Disease , 2006, Journal of neuropathology and experimental neurology.

[11]  Heikki Tanila,et al.  Gender differences in the amount and deposition of amyloidβ in APPswe and PS1 double transgenic mice , 2003, Neurobiology of Disease.

[12]  Kazuhiko Yanai,et al.  2-(2-[2-Dimethylaminothiazol-5-yl]Ethenyl)-6- (2-[Fluoro]Ethoxy)Benzoxazole: A Novel PET Agent for In Vivo Detection of Dense Amyloid Plaques in Alzheimer's Disease Patients , 2007, Journal of Nuclear Medicine.

[13]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[14]  Koji Abe,et al.  Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. , 2005, The American journal of pathology.

[15]  R. Mayeux,et al.  Hippocampal and entorhinal atrophy in mild cognitive impairment , 2007, Neurology.

[16]  Wen-Lang Lin,et al.  Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein , 2000, Nature Genetics.

[17]  M F Huque,et al.  Some comments on frequently used multiple endpoint adjustment methods in clinical trials. , 1997, Statistics in medicine.

[18]  J. Trojanowski,et al.  Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. , 2006, Annual review of pathology.

[19]  Alan C. Evans,et al.  Longitudinal neuroanatomical changes determined by deformation-based morphometry in a mouse model of Alzheimer's disease , 2008, NeuroImage.

[20]  L. Li,et al.  Impaired Eyeblink Conditioning and Decreased Hippocampal Volume in PDAPP V717F Mice , 2002, Neurobiology of Disease.

[21]  Guido Gerig,et al.  User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability , 2006, NeuroImage.

[22]  Daniel Rueckert,et al.  Longitudinal regional brain volume changes quantified in normal aging and Alzheimer's APP×PS1 mice using MRI , 2009, Brain Research.

[23]  B. Hyman,et al.  Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function , 2005, Science.

[24]  J. Morrison,et al.  Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease , 2003, Neurology.

[25]  C. Jack,et al.  MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment , 2008, Neurology.

[26]  Alejandra del C. Alonso,et al.  Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules , 1996, Nature Medicine.

[27]  Hirotaka Yoshida,et al.  Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein , 2002, The Journal of Neuroscience.

[28]  V. Hachinski,et al.  A NEW DEFINITION OF ALZHEIMER'S DISEASE: A HIPPOCAMPAL DEMENTIA , 1985, The Lancet.

[29]  K. Ashe,et al.  Age-Dependent Neurofibrillary Tangle Formation, Neuron Loss, and Memory Impairment in a Mouse Model of Human Tauopathy (P301L) , 2005, The Journal of Neuroscience.

[30]  et al.,et al.  Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline , 2008, NeuroImage.

[31]  M. Albert,et al.  MRI measures of entorhinal cortex vs hippocampus in preclinical AD , 2002, Neurology.

[32]  Kiralee M. Hayashi,et al.  Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. , 2006, Archives of neurology.

[33]  Bin Zhang,et al.  Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model , 2007, Neuron.

[34]  G WhittakerP,et al.  共やくエクイン・エストロゲン(Premarin)服用閉経婦人の血清エクイリン,エストロン,エストラジオール値 , 1980 .

[35]  Russell D. Wolfinger,et al.  SAS for Mixed Models, Second Edition , 2006 .

[36]  Clifford R Jack,et al.  Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[37]  B. Hyman,et al.  Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. , 2006, The American journal of pathology.

[38]  O. Keene,et al.  The log transformation is special. , 1995, Statistics in medicine.

[39]  N. Schuff,et al.  Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease , 2001, Journal of neurology, neurosurgery, and psychiatry.